title: [Multifocal serous chorioretinopathy secondary to the use of MEK inhibitors: Illustration and example of management through two case reports].
abstract: New targeted treatments are being used for patients affected by certain types of cancers with specific gene dysregulation. These new treatments transform the prognosis for the patients but the exact way in which they work is often incompletely known. This can prove to be problematic with regard to potential side effects. Ophthalmologic side effects are particularly difficult to detect in animal models. MEK inhibitors are among these new targeted treatments for which the indications are broad. One of the reported side effects of MEK inhibitors is the appearance of atypical multifocal serous chorioretinopathies which, when present, occur rapidly after starting the treatment and disappear soon after stopping it. We report two documented cases of serous chorioretinopathies secondary to the use of selumetinib, an MEK inhibitor. Both patients were followed for several months after initiating the treatment, using angiography, OCT, and filtered photographs. Only a very few cases have been reported, and the detailed description of two clear-cut cases and their management, as well as a review of the current literature, seems a good way to approach the management of this complication.
authors.affiliation: Service d'ophtalmologie, CHU Gabriel-Montpied, 58, rue Montalembert, 63000 Clermont-Ferrand, France. Electronic address: adrien.coutu@gmail.com.
authors.forename: A
authors.initials: A
authors.lastname: Coutu
authors.affiliation: Service d'ophtalmologie, CHU Gabriel-Montpied, 58, rue Montalembert, 63000 Clermont-Ferrand, France.
authors.forename: F
authors.initials: F
authors.lastname: Farguette
authors.affiliation: Service de pneumologie, CHU Gabriel-Montpied, 58, rue Montalembert, 63000 Clermont-Ferrand, France.
authors.forename: G
authors.initials: G
authors.lastname: Jeannin
authors.affiliation: Service d'ophtalmologie, CHU Gabriel-Montpied, 58, rue Montalembert, 63000 Clermont-Ferrand, France.
authors.forename: F
authors.initials: F
authors.lastname: Chiambaretta
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001562:Benzimidazoles / Q000009:adverse effects* / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D056833:Central Serous Chorioretinopathy / Q000139:chemically induced* / Q000175:diagnosis; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D020929:Mitogen-Activated Protein Kinase Kinases / Q000037:antagonists & inhibitors*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D041623:Tomography, Optical Coherence
chemical_list: C517975:AZD 6244; D000970:Antineoplastic Agents; D001562:Benzimidazoles; D047428:Protein Kinase Inhibitors; D020929:Mitogen-Activated Protein Kinase Kinases
keywords: Adverse effect; Cancer treatment; Chorioretinopathy; Choriorétinopathie; Effet indésirable; Inhibiteur MEK; MEK inhibitor; Selumetinib; Sélumetinib; Traitement des cancers